Oncolytics Enters into Sponsorship Agreement with NCIC CTG
News Jun 06, 2012
Oncolytics Biotech Inc. has announced that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic non-small cell lung cancer ("NSCLC").
"This agreement expands our program with the NCIC CTG to a total of three randomized studies, including the colorectal and prostate studies we announced earlier in 2012," said Dr. Brad Thompson, President and CEO of Oncolytics.
Dr. Thompson continued, "This study builds upon both of our existing NSCLC clinical studies, as well as clinical research combining REOLYSIN® with docetaxel."
The study will be an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN.
Patients with squamous cell histology will be treated with REOLYSIN given in combination with docetaxel versus docetaxel alone.
Patients with non-squamous cell histology will be treated with REOLYSIN given in combination with pemetrexed versus pemetrexed alone.
Approximately 150 total response evaluable patients will be enrolled, after a patient safety run in.
Conference Call Details
Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast on Tuesday, June 5th, 2012 at 7:00 a.m. MT (9:00 a.m. ET) to discuss in more depth the Company's randomized Phase II clinical trial program.
To access the conference call by telephone, dial 1-647-427-7450 or 1-888-231-8191.
A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/detail/986501/1062975 or through the Company's website at www.oncolyticsbiotech.com/presentations.
Please connect at least 10 minutes prior to the webcast to ensure adequate time for any software download that may be needed.
A replay of the webcast will be available at www.oncolyticsbiotech.com and will also be available by telephone through June 12th, 2012.
To access the telephone replay, dial 1-416-849-0833 or 1-855-859-2056 and enter reservation number 88541070 followed by the number sign.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018